← back to search

Dong Wang

Harbin Medical University · CN
Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, and DNA Repair Mechanisms.
h-index
31
citations
4,228
works
228
NIH funding
primary concept
Medicine
email

Recent publications

Immune cells in systemic lupus erythematosus: biology and traditional Chinese medicine therapy
Acta Pharmacologica Sinica 2025cited by 4position: middledoi
P3.12.31 Rezivertinib in Advanced NSCLC Patients With EGFR T790M Mutation via Tissue/Plasma Samples: Pooled Analysis of 2 Clinical Studies
Journal of Thoracic Oncology 2025cited by 0position: middledoi
1425P Efficacy and safety of KN026 in combination with chemotherapy in patients (pts) with unresectable or metastatic HER2 positive gastric or gastroesophageal cancers (GC/GEJC) after first-line treatment with a trastuzumab-containing regimen
Annals of Oncology 2024cited by 5position: middledoi
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
The Lancet 2023cited by 645position: middledoi
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
JAMA 2023cited by 346position: middledoi
The value of lactate dehydrogenase to albumin ratio and immune inflammation biomarkers in colorectal cancer
Frontiers in Surgery 2023cited by 17position: lastdoi
MALT1 Positively Relates to T Helper 1 and T Helper 17 cells, and Serves as a Potential Biomarker for Predicting 30-Day Mortality in Stanford Type A Aortic Dissection Patients
The Tohoku Journal of Experimental Medicine 2023cited by 1position: middledoi
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
Journal of Clinical Oncology 2022cited by 166position: middledoi
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Journal of Thoracic Oncology 2021cited by 273position: middledoi
Clinical Features and Prognostic Factors of Children with Chronic Active Epstein-Barr Virus Infection: A Retrospective Analysis of a Single Center
The Journal of Pediatrics 2021cited by 10position: middledoi
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
Journal of Hematology & Oncology 2020cited by 50position: middledoi
Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first‑line therapy in patients with extensive‑stage small cell lung cancer
Oncology Letters 2019cited by 10position: middledoi
Pretreatment of ferulic acid attenuates inflammation and oxidative stress in a rat model of lipopolysaccharide-induced acute respiratory distress syndrome
International Journal of Immunopathology and Pharmacology 2018cited by 54position: middledoi
Multiplex PCR coupled with propidium monoazide for the detection of viable Cronobacter sakazakii, Bacillus cereus, and Salmonella spp. in milk and milk products
Journal of Dairy Science 2017cited by 56position: middledoi
[China Experts Consensus on the Diagnosis and Treatment of Brain Metastases of Lung Cancer (2017 version)].
PubMed 2017cited by 27position: middledoi
China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)
Asia-Pacific Journal of Clinical Oncology 2016cited by 44position: middledoi
Comparison of the expression and function of Lin28A and Lin28B in colon cancer
Oncotarget 2016cited by 28position: middledoi
A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker.
Journal of Clinical Oncology 2014cited by 4position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 2 papers (2014–2019)Yunpeng Liu · Capital Medical University2 papers (2019–2021)Yan Yu · Army Medical University2 papers (2019–2021)Xiaoqing Liu · Chinese PLA General Hospital2 papers (2014–2019)Jianhua Shi · Harbin Medical University2 papers (2014–2019)Jiwei Liu · Harbin Medical University2 papers (2014–2019)Cheng Huang · Fujian Medical University2 papers (2014–2019) · 2 papers (2014–2019)Yun Fan · Zhejiang Cancer Hospital2 papers (2014–2019)Helong Zhang · Jilin University2 papers (2014–2019)Shukui Qin · Affiliated Hospital of Southwest Medical University2 papers (2014–2019)Ying Cheng · Changzhi University2 papers (2014–2019)Junqing Zong · Shanxi Medical University1 papers (2023–2023)Yunze Zhao · National Center for Women and Children’s Health, China CDC1 papers (2021–2021)Yanjun Du · Guiyang Medical University1 papers (2024–2024)Yushi Liu · Dartmouth College1 papers (2024–2024)Rui Zhang · Second Military Medical University1 papers (2024–2024)Shuang Yu · Fudan University1 papers (2017–2017)Hengyi Xu · Nanchang University1 papers (2017–2017)Zhongjie Zhang · Zhejiang Energy Group (China)1 papers (2023–2023)